DNLIDenali Therapeutics Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $0
- Operating margin
- —
- EBITDA
- −$544M
- 13% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $49M | $105M | $331M | $0 | $0 | |
| Operating income | −$296M | −$341M | −$197M | −$487M | −$555M | 14% |
| Net income | −$291M | −$326M | −$145M | −$423M | −$513M | 21% |
| Operating cash flow | −$211M | −$245M | −$358M | −$348M | −$413M | 19% |
| Capex | $9M | $18M | $13M | $16M | $10M | 40% |
| Stock-based comp | $85M | $100M | $108M | $103M | $100M | 3.2% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $364K · 4
- Net
- −$364K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $5M | $1M | 20 | 125 |
| FY2024 | $7M | $6M | 24 | 93 |
| FY2023 | $8M | −$813K | 26 | 94 |
| FY2022 | $9M | −$12M | 33 | 90 |
| FY2021 | $13M | −$58M | 53 | 100 |